Table 2.
Univariate analysis for progression free survival.
| Variant | Hazard ratio | 95% CI (Lower) | 95% CI (Upper) | p-value |
|---|---|---|---|---|
| Age at diagnosis, n | ||||
| <40 y | 1 | |||
| 40–64 y | 1.695 | 0.853 | 3.368 | 0.132 |
| >64 y | 2.529 | 1.232 | 5.192 | 0.011 |
| Sex, n | ||||
| Male | 1 | |||
| Female | 0.913 | 0.668 | 1.845 | 0.570 |
| Extent of surgical resection, n | ||||
| Gross total resection | 1 | |||
| Subtotal resection | 2.197 | 1.430 | 3.375 | 0.000 |
| Biopsy | 1.394 | 0.943 | 2.060 | 0.095 |
| MGMT status, n | ||||
| Positive | 0.811 | 0.398 | 1.651 | 0.563 |
| Negative | 1 | |||
| Comorbidities at diagnosis, n | ||||
| Diabetes Mellitus | 1.269 | 0.873 | 1.845 | 0.211 |
| Hypertension | 1.385 | 1.016 | 1.887 | 0.039 |
| Ischemic heart disease | 3.108 | 1.506 | 6.412 | 0.002 |
| RT total dose (Gy), n | ||||
| ≥ 56 | 1 | |||
| 36–50 | 1.236 | 0.697 | 2.189 | 0.468 |
| ≤32 | 13.120 | 5.175 | 33.263 | 0.000 |
| No. of adjuvant Temozolomide cycles*, n | ||||
| 0 | 1 | |||
| 1–3 | 1.290 | 0.681 | 2.442 | 0.434 |
| 4–6 | 1.030 | 0.525 | 2.023 | 0.931 |
| 7–9 | 0.482 | 0.226 | 1.027 | 0.059 |
| ≥10 | 0.297 | 0.152 | 0.582 | 0.000 |
| Patients who switched to 2nd line therapy | ||||
| Yes | 0.898 | 0.656 | 1.229 | 0.502 |
| No | 1 | |||
| Pauses during RT | ||||
| Yes | 0.746 | 0.443 | 1.255 | 0.269 |
| No | 1 | |||
| Steroid use during RT | ||||
| Yes | 1.485 | 0.868 | 2.542 | 0.149 |
| No | 1 | |||
| *Post concomitant therapy with RT + TMZ. | ||||
Hazard ratio (HR) less than 1 – better overall survival, >1 – worse overall survival; P-value < 0.05 – statistically significant.